Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma

Explore clinical trials studying Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma. Study availability and eligibility vary by location and protocol.

9 public trials 5 recruiting studies

Refine in advanced search Browse all conditions

Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma trial results

Recruiting

CD38 Targeted -PET/ CT for Multiple Myeloma

NCT07782944

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +15 more
Locations: The First Affliated Hospital of Guilin Medical University Guilin, Guangxi, China

View Trial Details

Recruiting

Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors

NCT07410494

Conditions: Acute Myeloid Leukemia (AML), Adenocarcinoma, Adnexal Diseases, +92 more
Locations: District One Hospital Beijing, Beijing Municipality, China

View Trial Details

Recruiting

Pragmatic Geriatric Assessment Before CAR-T or Bispecific Antibody Therapy to Predict Side Effects and Outcomes in Older Patients (GA-ACT Trial)

NCT07309497

Conditions: Bispecific Antibody, Blood Protein Disorders, CART Therapy, +18 more
Locations: Inselspital Bern Bern, Switzerland

Universitätsspital Zürich Zurich, Switzerland

View Trial Details

Recruiting

Randomised Controlled Trial of Artificial Intelligence-assisted Health Education

NCT07305337

Conditions: Adherence Interventions, Behavior, Blood Protein Disorders, +25 more
Locations: Zhongnan Hospital of Wuhan University Wuhan, Hubei, China

View Trial Details

Recruiting

Reduced-Dose Apixaban and Rivaroxaban Versus Low-Molecular-Weight Heparin in Patients With Hematologic Malignancies

NCT07270263

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Embolism, +29 more
Locations: Department of Haematology & Transplantology Gdansk, Pomeranian Voivodeship, Poland

View Trial Details

Not yet recruiting

BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma and Multiple Myeloma

NCT07771361

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +28 more
Locations: Not specified

View Trial Details

Not yet recruiting

Why Patients Decline or Are Being Deemed Ineligible to Receive Home-based Treatment: a Mixed Methods Study

NCT07634263

Conditions: Behavior, Blood Protein Disorders, Cardiovascular Diseases, +23 more
Locations: Copenhagen University Hospital (Rigshospitalet) Copenhagen, Denmark

Odense University Hospital Odense, Denmark

Sjællands Universitets Hospital Roskilde, Denmark

View Trial Details

Not yet recruiting

Cognitive Impairment in Patients Undergoing Cell- and Antibody-based Immunotherapies for Haematological Malignancies: The COGNITOX Study

NCT07558057

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +19 more
Locations: Aarhus University Hospital Aarhus, Denmark

View Trial Details

Completed

Phase I Study of MIK665, a Mcl-1 Inhibitor, in Patients With Refractory or Relapsed Lymphoma or Multiple Myeloma

NCT02992483

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +15 more
Locations: MD Anderson Cancer Center/University of Texas MD Anderson CC Houston, Texas, United States

Novartis Investigative Site Heidelberg, Victoria, Australia

Novartis Investigative Site Nantes, France

Novartis Investigative Site Heidelberg, Germany

View Trial Details

Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma

Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma trial results

Related conditions